Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - The objective of this multi-institutional study was to determine the comparative effectiveness and cost-effectiveness of abiraterone acetate (AA) versus enzalutamide (ENZ). They used population, intervention, comparison, and outcomes (PICO) to evaluate the comparability of the pivotal phase 3 clinical trials: COU-AA-301 for AA and AFFIRM for ENZ. Bucher method and Bayesian statistics was used to conduct an indirect treatment comparison. A survival-based Markov cohort model with 3 health states (progression-free, progressed, and death) was developed to estimate cost-effectiveness over a lifetime horizon. For a 30-day supply of AA and ENZ, the average wholesale prices were $7674 and $8940, respectively. They utilized one-way sensitivity analyses for all probability, utility, and cost values incorporated into the model.

auaAfter accounting for important differences in comparators and background treatments, the results of indirect treatment comparison showed no significant difference in overall survival for AA compared to ENZ. In the base case of the economic analysis, AA was found to provide an annual cost savings of $13,322 per patient and this is primarily due to higher acquisition costs of ENZ. Quality-adjusted life years gained were comparable for AA and ENZ. These results were supported by sensitivity analyses. AA and ENZ are 2 treatment options for patients with metastatic castration-resistant prostate cancer. Presently, there is great interest in understanding the relative clinical and economic value of these therapies. The results of this indirect treatment comparison shows that both AA and ENZ can have similar efficacy in terms of OS in post chemotherapy mCRPC patients; However, it appears that AA is more cost effective compared to ENZ.

Click HERE to view the poster from this session

Presented by Melissa Thompson at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Burlington, ON Canada

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe